ADTC (M) 24/04
Minutes 35 - 44

NHS GREATER GLASGOW AND CLYDE

Minutes of the Meeting of the
Area Drugs and Therapeutics Committee
held on Monday 19 August 2024 at 2.00pm
via Microsoft Teams

PRESENT

Dr Scott Muir (in the Chair)

Katie Adair	Kay McAllister
Ronnie Burns	Anne-Mairi McLean
Cristina Coelho	Elaine McIvor
Chloe Docherty	Ishtiaq Mohammed
Ysobel Gourlay	Aileen Muir
Rodger Hardman	Rob Puckett
Chis Jones	Faria Qureshi
Peter Kewin	Helen A. Smith

IN ATTENDANCE

Natalie Kerr	Secretariat (Minute)

			ACTION BY
35.	**CHAIR'S STATEMENT**		
	The Chair reminded members that papers and proceedings related to SMC advice were, in some cases, confidential, and should not be disclosed before the relevant embargo dates. Members were reminded to make relevant declarations of interest in line with Board policy. Members were advised not to speak with members of the press on ADTC business but to refer such enquiries to the Board Press Liaison Office. **NOTED**		
36.	**WELCOME AND APOLOGIES**		
	The Chair welcomed those present to the August meeting of the Area Drugs and Therapeutics Committee.		

			ACTION BY
	Apologies for absence were noted on behalf of Gail Caldwell, Fiona Thomson and Gerard McKay. **NOTED**		
37.	**MINUTES OF PREVIOUS MEETING**		
	The Committee considered the minute of the meeting held on Monday, 17th June 2024 and were content to accept these as an accurate record of the meeting. **APPROVED**		
38.	**MATTERS ARISING**		
	There were no matters arising. **NOTED**		
39.	**NEW MEDICINES FOR CONSIDERATION**		
(i)	**Report on SMC Product Assessments**		
	Members were asked to declare any interests specific or non-specific, personal or non-personal, on any of the drugs being discussed on an individual basis. No declarations of interest were made. **NOTED**		
(ii)	**West of Scotland Cancer Network Prescribing Advisory Subgroup Reports**		
	The Committee noted the summary of advice for June 2024. **NOTED**		
40.	**ADTC SUMCOMMITTEE SIX MONTHLY REPORTS**		
a)	**Safer Use of Medicines**		
	There was no update available at this time. **NOTED**		

			ACTION BY
b)	**Communications Subcommittee**		
	Ms Elaine McIvor presented the paper 'Communication Subcommittee Six Monthly Report' [Paper 24/21] and highlighted the following: • The Subcommittee continued to be very busy. • 40 Medicines Update blogs were published this year. • A number of blogs series were now published. • Ongoing use of Twitter/X to publicise the vlogs. • Promotional activities remained on-going. • Introduction of SWAY last year to develop blogs to increase accessibility. The next step was to look at how SWAY could be utilised to check statistics. The Committee were content to note the update. **NOTED**		
41.	**ADTC SUBCOMMITTEE UPDATES**		
	a) Prescribing Interface Dr Roger Hardman provided a verbal update, highlighting the following: • An update was provided in relation to the interface between Primary Care and Secondary Care in terms of inpatient prescribing. • Denosumab Shared Care Agreement had been approved by LMC which would be updated soon. The Committee were content to note the update. **NOTED**		
	b) Patient Group Directive No specific update. **NOTED**		
	c) Medicines Utilisation Update		

			ACTION BY
	Dr Amit Verma informed the Committee there was no specific update as the Committee had not met since the last meeting. There was a meeting this week, therefore an update would be provided at the next ADTC meeting in October. **NOTED**		
	d) Non-Medicines Utilisation Update Ms Mairi-Anne McLean informed the Committee there was a meeting scheduled to take place this week, therefore an update would be provided at the next ADTC meeting in October. Ms McLean noted compliance was up to date however, getting compliance data was challenging. Ms McLean would provide a further update at the next ADTC meeting in October . The Committee were content to note the update. **NOTED**		
	e) Antimicrobial Subcommittee Update Ms Ysobel Gourlay provided a verbal update, highlighting the following: • Two papers had been written as updates of guidelines and Terms of Reference which were being submitted to the Committee next week. The Committee were content to note the update. **NOTED**		
42.	**HEPMA Progress Report**		
	Mr Rob Puckett provided a verbal update, highlighting the following: • Work taking place to get all Primary Care Pharmacists access to HEPMA applications. • Feedback received from North and South sector teams regarding concerns on double dosing. The Committee were content to note the update.		

			ACTION BY
	NOTED		
43.	**ADTC Collaborative Update**		
	Ms Faria Qureshi informed the Committee there were no significant updates as the Committee had not met since the last ADTC meeting. The next meeting was taking place this week, therefore an update would be provided at the next ADTC meeting in October. **NOTED**		
44.	**Yellow Card Annual Report for Scotland 2022 – 2023**		
	The Committee were content to note the paper. **NOTED**		
45.	**Any Other Business**		
	The Chair invited the Committee to raise any other business. No further business was raised. **NOTED**		
46.	**DATE OF NEXT SCHEDULED MEETING**		
	Monday, 07 October 2024 at 2pm, via Microsoft Teams		

Appendix 1:NHS Greater Glasgow and Clyde New Medicines Decisions

Date of ADTC Decisions: **19/08/2024**

empagliflozin

SMC2642

Jardiance® 0

Indication:

For the treatment of CKD in adults

ADTC Discussion points

Wider indication for use In CKD than dapagliflozin noted.
Prescribers familiar with prescribing glifozins for various indications. No longer a need to have prescriber restrcitions.
Local CkD guidelines will require to be updated to reflect the use of empagliflozin

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

etranacogene dezaparvovec

SMC2649

Hemgenix® 0

Indication:

treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.

ADTC Discussion points

Decision deferred pending clarification of service requirements and National Services Scotland risk share arrangements

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

remdesivir

SMC2550

Veklury® 0

Indication:

treatment of COVID-19 in:
- adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

ADTC Discussion points

Prescribing will be in line with local Covid guidelines and SMC restrictions

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

follitropin delta

SMC2670

Rekovelle® 0

Indication:

Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

ADTC Discussion points

Still awaiting feedback from local specialist.
Defer decision until next ADTC meeting

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

dostarlimab

SMC2635

Jemperli® 0

Indication:

In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

ivosidenib

SMC2615

Tibsovo® 0

Indication:

In combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

Loncastuximab tesirine

SMC2609

Zynlonta® 0

Indication:

monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

nivolumab, relatlimab

SMC2645

Opdualag® 0

Indication:

First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:

07/10/2024

Local restrictions on use:

---

olaparib

SMC2617

Lynparza® 0

Indication:

In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

pembrolizumab

SMC2660

Keytruda® 0

Indication:

in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:

07/10/2024

Local restrictions on use:

---

pembrolizumab

SMC2589

Keytruda® 0

Indication:

As monotherapy for adults with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in the following settings:
- treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy.

As monotherapy for the treatment of the following MSI-H or dMMR tumours in adults with:
- advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation;
- unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved. For use in all of the SMC submission indications except for advanced or recurrent endometrial carcinoma as experts do not support its use.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

talazoparib

SMC2607

Talzenna® 0

Indication:

Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

ADTC Discussion points

Recommended for addition to Formulary by Regional Cancer Advisory Group.. Regional protocol for use has been approved.

ADTC Decision:

Routinely available in line with local or regional guidance

Local restrictions on use:

---

trifluridine, tipiracil

SMC2654

Lonsurf® 0

Indication:

In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:

07/10/2024

Local restrictions on use:

---

fezolinetant

SMC2702

Veoza® 0

Indication:

Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

ADTC Discussion points

Not available as not recommended for use in NHS Scotland due to a company non-submission.

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

lenacapavir

SMC2691

Sunlenca® 0

Indication:

Film-coated tablets: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection
Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen..

ADTC Discussion points

Not avaiable as not recommnded for use in NHS Scotland due to a ompany non-submisison.

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

nivolumab

SMC2704

Opdivo® 0

Indication:

Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma

ADTC Discussion points

Not available for the stated indication as not recommended for use due to a company non-submission

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

remimazolam

SMC2692

Byfavo® 0

Indication:

Adults for intravenous induction and maintenance of general anaesthesia.

ADTC Discussion points

Not available as not recommended for use in NHS Scotland due to a company non-submission.

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

talquetamab

SMC2705

Talvey® 0

Indication:

Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

ADTC Discussion points

Not available as not recommended for use in NHS Scotland due to a company non-submission.

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

trastuzumab deruxtecan

SMC2693

Enhertu® 0

Indication:

Monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

ADTC Discussion points

Not available for the stated indication as not recommended for use due to a company non-submission

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

trastuzumab deruxtecan

SMC2706

Enhertu® 0

Indication:

Monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

ADTC Discussion points

Not available for the stated indication as not recommended for use due to a company non-submission

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

pembrolizumab

SMC2644

Keytruda®

0

Indication:

in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

ADTC Discussion points

Not available for the stated indication as not recommended for use.

ADTC Decision:

Not routinely available as not recommended for use in NHSScotland

Local restrictions on use:

---

dasatinib

NCMAG116

0

Indication:

Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) integrated with chemotherapy

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:

07/10/2024

Local restrictions on use:

---

dasatinib

NCMAG117

0

Indication:

Dasatinib for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:

07/10/2002

Local restrictions on use:

Esketamine

SMC2258

Spravato® 0

Indication:

In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

ADTC Discussion points

No request to add to the GGC Formulary received from the mental health service.
Original SMC advice issued August 2020

ADTC Decision:

Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)

Local restrictions on use:

---

glofitamab

SMC2614

Columvi® 0

Indication:

Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

epcoritamab

SMC2632

Tepkinly® 0

Indication:

Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

ADTC Discussion points

Referred to RCAG for advice

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

mavacamten

SMC2618

Camzyos® 0

Indication:

Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

ADTC Discussion points

Decision to be deferred.
Genetic phenotyping service is currently unavailable nationally and. there are also local service implications for ongoing monitoring.
Defer until service provision has been agreed.

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

momelotinib

SMC2636

Omjjara® 0

Indication:

Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

ADTC Discussion points

Awating feedback from RCAG

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

Semaglutide

SMC2497

Wegovy 0

Indication:

An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
•≧30kg/m2 (obesity), or
•≧27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

ADTC Discussion points

National SLWG looking at consensus statement regarding GLP1receptor agonists for weight management to help guide health boards. It was noted that there are significant local service implications and global supply issues ongoing. Further local implementation plans are needed. Decision on formular to be determined by product availability and service delivery.

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
09/12/2024

Local restrictions on use:

BMI of ≥30kg/m2* in the presence of at least one weight-related comorbidity. Patients should be treated in a specialist weight management service.
*A lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.

---

tirzepatide

SMC2653

Mounjaro® 0

Indication:

For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

ADTC Discussion points

Decision deferred until local implementation plans on service dleivery are agreed.

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
09/12/2024

Local restrictions on use:

---

voretigene neparvovec

SMC2641

Luxturna® 0

Indication:

Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

ADTC Discussion points

Patients will be referred to a specialist national centre for treatment.
Ongoing monitoring of patients will be undertaken locally.
Agreed not to be included on the GGC Formulary but can be prescribed to suitable GGC patients.

ADTC Decision:

Routinely available from a specialist centre in another health board

Local restrictions on use:

---

birch bark extract

SMC2651

Filsuvez® 0

Indication:

treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older

ADTC Discussion points

Decsion deferred until Scottish Government notification that medicine has been included on the national ultra-oprhan risk share scheme

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:

---

pegunigalsidase alfa

SMC2665

Elfabrio® 0

Indication:

for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).

ADTC Discussion points

Decsion deferred until Scottish Government notification that medicine has been included on the national risk share scheme

ADTC Decision:

Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:
07/10/2024

Local restrictions on use:
